10x Genomics (TXG) – StreetInsider.com Reports
-
10X Genomics (TXG) PT Lowered to $55 at Deutsche Bank
-
10X Genomics (TXG) PT Lowered to $45 at Barclays
-
CFRA Upgrades 10X Genomics (TXG) to Buy
-
10x Genomics (TXG) Commercially Launches Visium HD Spatial Gene Expression Assay
-
10x Genomics (TXG) Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
-
10x Genomics (TXG) Begins Commercial Shipments of Chromium GEM-X Products
-
10X Genomics (TXG) PT Raised to $52 at UBS
-
10X Genomics (TXG) PT Lowered to $58 at Morgan Stanley
-
10X Genomics (TXG) PT Lowered to $63 at Stifel
-
10X Genomics (TXG) PT Lowered to $65 at Canaccord Genuity
-
10x Genomics (TXG) Misses Q4 EPS by 6c, provides guidance
-
10X Genomics (TXG) PT Lowered to $60 at Deutsche Bank
-
10X Genomics (TXG) PT Raised to $55 at Barclays
-
10x Genomics (TXG) Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
10x Genomics (TXG) Launches Xenium Catalyst Network
-
Guggenheim Starts 10X Genomics (TXG) at Buy
-
Wolfe Research Starts 10X Genomics (TXG) at Outperform
-
BofA Securities Upgrades 10X Genomics (TXG) to Neutral, 'there are incremental reasons to turn more constructive'
-
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString Technologies (NSTG)
-
10X Genomics (TXG) PT Lowered to $44 at UBS
-
OWKIN Integrates 10x Genomics (TXG) Spatial Omics and Single-Cell Technologies to the MOSAIC Study
-
10X Genomics (TXG) PT Lowered to $60 at Morgan Stanley
-
10X Genomics (TXG) PT Lowered to $65 at JPMorgan
-
10X Genomics (TXG) PT Lowered to $36 at BofA Securities
-
10X Genomics (TXG) PT Lowered to $55 at TD Cowen
-
10x Genomics (TXG) Misses Q3 EPS by 33c, provides guidance
-
10X Genomics (TXG) PT Lowered to $60 at TD Cowen
-
10x Genomics (TXG) Comments on Second UPC Preliminary Injunction Decision
-
10X Genomics (TXG) PT Lowered to $47 at Barclays
-
10x Genomics (TXG) Wins Injunction From Unified Patent Court Banning Sales of NanoString's (NSTG) CosMx Products in Europe
-
10x Genomics (TXG) Announces New High-Throughput Multiomic Profiling Kit
-
10x Genomics (TXG) Passes 100 Xenium Analyzer Shipments
-
10X Genomics (TXG) PT Raised to $70 at TD Cowen
-
10X Genomics (TXG) PT Raised to $62 at UBS
-
10X Genomics (TXG) PT Raised to $70 at Canaccord Genuity
-
10X Genomics (TXG) PT Raised to $66 at Barclays
-
10x Genomics (TXG) Misses Q2 EPS by 13c; Offers FY23 Guidance
-
10X Genomics (TXG) PT Raised to $30 at Goldman Sachs
-
10x Genomics (TXG) Reports Publication of CAR T-Cell Study Enabled by its Genomics Single Cell Technology
-
JPMorgan Assumes 10X Genomics (TXG) at Overweight
-
10x Genomics (TXG) Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products
-
10x Genomics (TXG) Launches Visium CytAssist Gene and Protein Expression Assay
-
10x Genomics (TXG) Wins Permanent Injunction Against NanoString's (NSTG) CosMx Products
-
NanoString Technologies (NSTG) Responds to Decision of the Regional Court of Munich
-
Barclays Starts 10X Genomics (TXG) at Overweight
-
10X Genomics (TXG) PT Raised to $58 at UBS
-
10X Genomics (TXG) PT Raised to $68 at Stifel
-
10X Genomics (TXG) PT Raised to $65 at JPMorgan
-
10x Genomics (TXG) Misses Q1 EPS by 10c; Offers FY23 Revenue Guidance
-
10X Genomics (TXG) PT Raised to $54 at UBS
Back to TXG Stock Lookup